CN103347882B - 作为III型受体酪氨酸激酶抑制剂的取代的N-(1H-吲唑-4-基)咪唑并[1,2-a]吡啶-3-甲酰胺化合物 - Google Patents

作为III型受体酪氨酸激酶抑制剂的取代的N-(1H-吲唑-4-基)咪唑并[1,2-a]吡啶-3-甲酰胺化合物 Download PDF

Info

Publication number
CN103347882B
CN103347882B CN201180067342.XA CN201180067342A CN103347882B CN 103347882 B CN103347882 B CN 103347882B CN 201180067342 A CN201180067342 A CN 201180067342A CN 103347882 B CN103347882 B CN 103347882B
Authority
CN
China
Prior art keywords
methyl
pyridine
imidazo
indazole
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180067342.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN103347882A (zh
Inventor
M.L.博伊斯
R.K.德莱尔
E.J.希肯
A.L.肯尼迪
D.A.马里斯卡
F.P.玛姆萨特
M.C.芒森
B.纽豪斯
B.拉斯特
J.P.里齐
M.E.罗德里格兹
G.T.托帕洛夫
赵千
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Array Biopharma Inc
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Priority to CN201610248287.9A priority Critical patent/CN105924437B/zh
Priority to CN201811311712.XA priority patent/CN109608449A/zh
Publication of CN103347882A publication Critical patent/CN103347882A/zh
Application granted granted Critical
Publication of CN103347882B publication Critical patent/CN103347882B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201180067342.XA 2010-12-13 2011-12-13 作为III型受体酪氨酸激酶抑制剂的取代的N-(1H-吲唑-4-基)咪唑并[1,2-a]吡啶-3-甲酰胺化合物 Expired - Fee Related CN103347882B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201610248287.9A CN105924437B (zh) 2010-12-13 2011-12-13 作为iii型受体酪氨酸激酶抑制剂的化合物
CN201811311712.XA CN109608449A (zh) 2010-12-13 2011-12-13 作为iii型受体酪氨酸激酶抑制剂的化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42254710P 2010-12-13 2010-12-13
US61/422,547 2010-12-13
PCT/US2011/064549 WO2012082689A1 (en) 2010-12-13 2011-12-13 SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN201610248287.9A Division CN105924437B (zh) 2010-12-13 2011-12-13 作为iii型受体酪氨酸激酶抑制剂的化合物
CN201811311712.XA Division CN109608449A (zh) 2010-12-13 2011-12-13 作为iii型受体酪氨酸激酶抑制剂的化合物

Publications (2)

Publication Number Publication Date
CN103347882A CN103347882A (zh) 2013-10-09
CN103347882B true CN103347882B (zh) 2016-05-11

Family

ID=45478484

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201180067342.XA Expired - Fee Related CN103347882B (zh) 2010-12-13 2011-12-13 作为III型受体酪氨酸激酶抑制剂的取代的N-(1H-吲唑-4-基)咪唑并[1,2-a]吡啶-3-甲酰胺化合物
CN201811311712.XA Pending CN109608449A (zh) 2010-12-13 2011-12-13 作为iii型受体酪氨酸激酶抑制剂的化合物
CN201610248287.9A Expired - Fee Related CN105924437B (zh) 2010-12-13 2011-12-13 作为iii型受体酪氨酸激酶抑制剂的化合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201811311712.XA Pending CN109608449A (zh) 2010-12-13 2011-12-13 作为iii型受体酪氨酸激酶抑制剂的化合物
CN201610248287.9A Expired - Fee Related CN105924437B (zh) 2010-12-13 2011-12-13 作为iii型受体酪氨酸激酶抑制剂的化合物

Country Status (32)

Country Link
US (3) US9174981B2 (enExample)
EP (1) EP2651939B1 (enExample)
JP (3) JP5868996B2 (enExample)
KR (1) KR101974665B1 (enExample)
CN (3) CN103347882B (enExample)
AU (3) AU2011344001B2 (enExample)
BR (1) BR112013014854B1 (enExample)
CA (2) CA2821712C (enExample)
CL (1) CL2013001712A1 (enExample)
CO (1) CO6751248A2 (enExample)
CR (1) CR20130349A (enExample)
DK (1) DK2651939T3 (enExample)
ES (1) ES2540996T3 (enExample)
HR (1) HRP20150571T1 (enExample)
HU (1) HUE025416T2 (enExample)
IL (1) IL226911A (enExample)
ME (1) ME02172B (enExample)
MX (1) MX2013006763A (enExample)
MY (1) MY172110A (enExample)
NZ (1) NZ613235A (enExample)
PH (1) PH12013501221A1 (enExample)
PL (1) PL2651939T3 (enExample)
PT (1) PT2651939E (enExample)
RS (1) RS54070B1 (enExample)
RU (1) RU2591195C2 (enExample)
SG (1) SG191129A1 (enExample)
SI (1) SI2651939T1 (enExample)
SM (1) SMT201500165B (enExample)
TW (1) TWI527813B (enExample)
UA (1) UA112425C2 (enExample)
UY (1) UY33801A (enExample)
WO (1) WO2012082689A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109608449A (zh) * 2010-12-13 2019-04-12 阵列生物制药公司 作为iii型受体酪氨酸激酶抑制剂的化合物

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101779630B1 (ko) * 2009-12-21 2017-09-18 어레이 바이오파마 인크. ｃＦＭＳ 억제제로서 치환된 Ｎ-（１Ｈ-인다졸-４-일）이미다조［１,２-ａ］피리딘-３-카복사미드 화합물
GB201315486D0 (en) * 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
CN104496891A (zh) * 2014-12-06 2015-04-08 哈尔滨工业大学 吡啶衍生物2-叔丁氧基-6-亚甲基氯吡啶的合成方法
CN104974078A (zh) * 2015-06-25 2015-10-14 黄荣辉 一种2-甲基-6-氯甲基吡啶盐酸盐的制备方法
US10836742B2 (en) 2015-08-11 2020-11-17 Neomed Institute N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals
US10501438B2 (en) 2015-08-11 2019-12-10 Neomed Institute Aryl-substituted dihydroquinolinones, their preparation and their use as pharmaceuticals
CN114605387A (zh) 2015-08-12 2022-06-10 埃皮吉纳提克斯股份有限公司 取代的苯并咪唑、它们的制备和它们作为药物的用途
US10501459B2 (en) 2015-10-21 2019-12-10 Neomed Institute Substituted imidazo[1,2-a]pyridines as bromodomain inhibitors
EP3974424A1 (en) * 2015-11-02 2022-03-30 Genase Therapeutics B.V. Tetrahydroindazoles and medical uses thereof
CN105198799A (zh) * 2015-11-03 2015-12-30 江苏梦得电镀化学品有限公司 一种2-甲基-6-氯甲基吡啶盐酸盐的制备方法
US10519151B2 (en) 2016-01-28 2019-12-31 Neomed Institute Substituted [1,2,4]triazolo[4,3-A]pyridines, their preparation and their use as pharmaceuticals
RU2744988C2 (ru) 2016-06-14 2021-03-17 Новартис Аг Соединения и композиции для подавления активности shp2
CN106187899B (zh) * 2016-06-28 2019-07-16 绍兴文理学院 一种氟代氮杂芳烃的合成方法
CN109790079B (zh) * 2016-07-29 2022-06-03 香港科技大学 有机锌试剂与杂环(拟)卤化物的C(sp3)-C(sp2)交叉偶联反应
WO2018083635A2 (en) 2016-11-04 2018-05-11 Auckland Uniservices Limited Tricyclic heterocyclic derivatives and uses thereof
JP6346368B1 (ja) * 2016-11-28 2018-06-20 エーザイ・アール・アンド・ディー・マネジメント株式会社 インダゾール誘導体の塩及びその結晶
WO2018213665A1 (en) 2017-05-19 2018-11-22 Syndax Pharmaceuticals, Inc. Combination therapies
MD3658552T2 (ro) 2017-07-28 2024-02-29 Yuhan Corp Procedeu de obținere a N-(5-((4-(4-((dimetilamino)metil)-3-fenil-1H-pirazol-1-il)pirimidin-2-il)amino)-4-metoxi-2-morfolinofenil)acrilamidei prin prin reacţia aminei corespunzătoare cu clorură de 3-halo-propionil
WO2019178129A1 (en) 2018-03-13 2019-09-19 Shire Human Genetic Therapies, Inc. Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof
CN111410654B (zh) * 2019-01-19 2022-05-17 江苏新元素医药科技有限公司 3-溴-5-(2-乙基咪唑并[1,2-a]吡啶-3-羰基)-2-羟基苯甲腈的合成
TWI841671B (zh) 2019-01-24 2024-05-11 日商第一三共股份有限公司 具有取代基之脲化合物
TWI759829B (zh) 2019-08-23 2022-04-01 財團法人生物技術開發中心 作為第iii型受體酪胺酸激酶抑制劑之雜環吡唑衍生物
PT4031547T (pt) 2019-09-18 2024-08-27 Takeda Pharmaceuticals Co Inibidores de calicreína plasmática e utilizações dos mesmos
WO2021055589A1 (en) 2019-09-18 2021-03-25 Shire Human Genetic Therapies, Inc. Heteroaryl plasma kallikrein inhibitors
WO2025146196A1 (zh) * 2024-01-04 2025-07-10 上海翰森生物医药科技有限公司 多环类衍生物抑制剂、其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101679423A (zh) * 2007-04-03 2010-03-24 阵列生物制药公司 作为受体酪氨酸激酶抑制剂的咪唑并[1,2-a]吡啶化合物
CN101679409A (zh) * 2006-12-22 2010-03-24 Astex治疗学有限公司 新颖化合物
CN102822170A (zh) * 2009-12-21 2012-12-12 阵列生物制药公司 作为cFMS抑制剂的取代的N-(1H-吲唑-4-基)咪唑并[1,2-a]吡啶-3-羧酰胺化合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
IL165262A0 (en) 2002-05-23 2005-12-18 Cytopia Pty Ltd Kinase inhibitors
FR2925901B1 (fr) 2008-01-02 2011-03-04 Sanofi Aventis DERIVES DE N-HETEROCYCLIQUE-IMIDAZO°1,2-a!PYRIDINE-2- CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
ES2526966T3 (es) * 2008-06-05 2015-01-19 Glaxo Group Limited Compuestos novedosos
TW201105669A (en) * 2009-07-30 2011-02-16 Irm Llc Compounds and compositions as Syk kinase inhibitors
JO3337B1 (ar) 2010-12-13 2019-03-13 Debiopharm Sa تركيبات صيدلية تشمل أليسبوريفير
UY33801A (es) 2010-12-13 2013-06-28 Array Biopharma Inc COMPUESTOS SUSTITUIDOS DE N-(1H-INDAZOL-4IL)IMIDAZO[1,2-a]PIRIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE LA TIROSINA QUINASA RECEPTORA DE TIPO III
CN102250246A (zh) * 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101679409A (zh) * 2006-12-22 2010-03-24 Astex治疗学有限公司 新颖化合物
CN101679423A (zh) * 2007-04-03 2010-03-24 阵列生物制药公司 作为受体酪氨酸激酶抑制剂的咪唑并[1,2-a]吡啶化合物
CN102822170A (zh) * 2009-12-21 2012-12-12 阵列生物制药公司 作为cFMS抑制剂的取代的N-(1H-吲唑-4-基)咪唑并[1,2-a]吡啶-3-羧酰胺化合物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109608449A (zh) * 2010-12-13 2019-04-12 阵列生物制药公司 作为iii型受体酪氨酸激酶抑制剂的化合物

Also Published As

Publication number Publication date
RU2591195C2 (ru) 2016-07-10
MY172110A (en) 2019-11-14
AU2018201903A1 (en) 2018-04-12
JP2018065835A (ja) 2018-04-26
AU2011344001B2 (en) 2016-06-30
CO6751248A2 (es) 2013-09-16
BR112013014854B1 (pt) 2020-12-08
HRP20150571T1 (xx) 2015-07-03
KR101974665B1 (ko) 2019-05-02
PH12013501221A1 (en) 2022-03-30
RU2013132758A (ru) 2015-01-20
AU2018201903B2 (en) 2019-09-19
TWI527813B (zh) 2016-04-01
US20130274244A1 (en) 2013-10-17
US20160002232A1 (en) 2016-01-07
EP2651939B1 (en) 2015-04-08
TW201305156A (zh) 2013-02-01
DK2651939T3 (en) 2015-06-01
CA2821712A1 (en) 2012-06-21
CN109608449A (zh) 2019-04-12
US9174981B2 (en) 2015-11-03
BR112013014854A8 (pt) 2018-03-27
CA2821712C (en) 2019-02-12
ME02172B (me) 2015-10-20
UY33801A (es) 2013-06-28
AU2016222468B2 (en) 2017-12-21
WO2012082689A1 (en) 2012-06-21
ES2540996T3 (es) 2015-07-15
NZ613235A (en) 2015-04-24
JP2016040303A (ja) 2016-03-24
SG191129A1 (en) 2013-07-31
US9809590B2 (en) 2017-11-07
SMT201500165B (it) 2015-09-07
PL2651939T3 (pl) 2015-10-30
AU2016222468A1 (en) 2016-09-22
JP2013545808A (ja) 2013-12-26
HK1190709A1 (en) 2014-07-11
UA112425C2 (uk) 2016-09-12
CN105924437A (zh) 2016-09-07
JP5868996B2 (ja) 2016-02-24
SI2651939T1 (sl) 2015-07-31
US10669269B2 (en) 2020-06-02
KR20140014109A (ko) 2014-02-05
CR20130349A (es) 2013-08-09
IL226911A (en) 2016-09-29
HUE025416T2 (en) 2016-02-29
PT2651939E (pt) 2015-08-04
RS54070B1 (sr) 2015-10-30
CN103347882A (zh) 2013-10-09
CN105924437B (zh) 2018-11-30
BR112013014854A2 (pt) 2016-10-18
US20180086758A1 (en) 2018-03-29
EP2651939A1 (en) 2013-10-23
MX2013006763A (es) 2014-01-08
CA3027814A1 (en) 2012-06-21
CL2013001712A1 (es) 2013-12-06

Similar Documents

Publication Publication Date Title
CN103347882B (zh) 作为III型受体酪氨酸激酶抑制剂的取代的N-(1H-吲唑-4-基)咪唑并[1,2-a]吡啶-3-甲酰胺化合物
KR101779630B1 (ko) ｃＦＭＳ 억제제로서 치환된 Ｎ-（１Ｈ-인다졸-４-일）이미다조［１,２-ａ］피리딘-３-카복사미드 화합물
AU2011344001A1 (en) Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors
WO2024046512A2 (zh) 含氮大环类化合物及其制备方法和医药用途
HK40007501A (en) Compounds as type iii receptor tyrosine kinase inhibitors
HK1228889B (zh) 作為iii型受體酪氨酸激酶抑制劑的化合物
HK1228889A1 (en) Compounds as type iii receptor tyrosine kinase inhibitors
HK1190709B (en) Substituted n-(1h-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type iii receptor tyrosine kinase inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160511

Termination date: 20211213